liver cancer
Conditions
Interventions
one:TACE+Oral administration of apatinib at 500mg/ day
two:Only TACE
Sponsors
The First Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) willing to sign the informed consent; (2) aged 18 to 75 years old male and female; (3) the primary liver cancer diagnosis standard: 1) have hepatitis b or hepatitis c, or have any reason to cause liver cirrhosis, at least every six months for an ultrasound and detection of AFP found intrahepatic diameter 2 cm or less nodules, dynamic enhanced MRI, dynamic enhanced CT and ultrasound imaging and the beauty show dynamic enhanced magnetic resonance imaging (MRI) at least two out of four examination showed arterial lesions significantly improved, portal or delay improved falling fast in fast out the typical characteristics of liver cancer, can make the clinical diagnosis of liver cancer; For nodules with > 2cm in diameter found in the liver, liver cancer can be clinically diagnosed as liver cancer as long as one of the four imaging examinations above has typical characteristics of liver cancer; 2) For patients with hepatitis b or hepatitis c, or liver cirrhosis caused by any reason, nodules with an diameter of 2cm in the liver can be found during follow-up. If none or only one of the four imaging examinations above has typical characteristics of liver cancer, liver biopsy or close imaging follow-up every 2-3 months can be conducted to establish the diagnosis; For the nodules with an intrahepatic diameter of > 2cm, the above four imaging examinations showed no typical characteristics of liver cancer, so liver biopsy was needed to establish the diagnosis; 3) With hepatitis b or hepatitis c, or any causes of cirrhosis of the liver, such as AFP, especially continues to increase, the four kinds of imaging examination should be performed to establish the diagnosis of liver cancer, such as not found intrahepatic nodules, beyond a pregnancy, active liver disease, reproductive embryonic origin above, under the premise of the digestive tract cancer tumor should be closely followed up the AFP levels and every 2-3 months once imaging review; (4) patients with primary liver cancer caused by various reasons, stage b-c of liver cancer BCLC.
Exclusion criteria
Exclusion criteria: (1) serum total bilirubin 44.5 mol/L (2) white blood cell count <1x10^9/L; (3) HIV infection; (4) patients with metastatic liver cancer; (5) patients with uncontrolled hypertension, diabetes or other serious heart and lung diseases; (6) pregnant and lactating women or women who do not exclude the possibility of pregnancy; (7) have participated in other drug trials within 3 months; (8) not suitable for participants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peripheral blood VEGF level; | — |
Contacts
Public ContactGuo Guihai
The First Affiliated Hospital of Nanchang University
Outcome results
None listed